Human papilloma virus vaccine for low and middle income countries: A step too soon?. Issue 11 (2nd November 2017)

• Record Type: Journal Article
• Authors: Jindal, Har Ashish; Kaur, Amanjot; Murugan, Sathiabalan
• Is Part Of: Human vaccines & immunotherapeutics. Volume 13:Issue 11(2017)
• Page Start: 2723
• Page End: 2725
• Publication Date: 2017-11-02
• Subjects: Cervical -- cancer -- HPV -- vaccine; Vaccines -- Periodicals; 615.372
• DOI: 10.1080/21645515.2017.1358837
• Languages: English
• ISSNs: 2164-5515

Abstract

ABSTRACT: Cervical Cancer is the most common genital cancer in women in India. Human papilloma virus (HPV) causes precancerous lesions that often develop into cervical cancer suggesting that cervical cancer has an infective etiology and is potentially preventable by preventing HPV infection through the use of HPV vaccines. The incidence in developing nations is largely under-reported due to large population size, poor and incomplete database. HPV vaccine is being considered for inclusion in the immunization schedule of developing countries. An effective surveillance system for a vaccine requires that the baseline incidence, prevalence, and mortality rates of cervical cancer are established for a given population. The lessons learnt from the polio vaccine must be applied to every vaccine being introduced for its optimal utilization. HPV vaccines might be used as a cost-effective scientific intervention to prevent cervical cancer but need to be combined with good screening methods in developing countries for a paradigm shift in the management of cervical cancer